Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

PercuSense Announces Project with the University of Melbourne funded by The Helmsley Charitable Trust to Develop a Single Sensor Continuous Glucose and Ketone Monitor

By combining glucose and ketone on a single implantable sensor, PercuSense aims to reduce the risk of diabetic ketoacidosis, reducing the burden and ultimately increasing the treatment options for people with diabetes.


News provided by

PercuSense, Inc.

Nov 02, 2020, 14:00 ET

Share this article

Share toX

Share this article

Share toX


VALENCIA, Calif., Nov. 2, 2020 /PRNewswire-PRWeb/ -- PercuSense, an intelligent biosensor and digital health company, announced it has been awarded a $2.5 million program-related investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust. PercuSense will use the funding to continue development on its novel continuous monitoring system that measures both glucose and ketones on a single minimally invasive probe. PercuSense will also support the University of Melbourne's efforts to conduct pre-clinical testing and the first-in-human clinical studies, funded through a separate grant from Helmsley.

Diabetic ketoacidosis (DKA) is a potentially life-threatening increase in ketone levels in people with diabetes, which results in over 200,000 hospitalizations and over $5 billion in healthcare expenditure in the U.S. annually. Additionally, SGLT2 inhibitors, a promising class of glucose lowering drugs that offer additional health benefits for people with diabetes, have not yet been FDA-approved for type 1 diabetes in part because they have been shown to increase the risk of DKA in type 1 diabetes. Successful development of PercuSense's continuous glucose and ketone monitoring system could decrease the risk of DKA and allow for more people with type 1 diabetes to reap the benefits of SGLT2 inhibitors.

Our hope is that CGKM will be the standard of care in the future, and we are excited to support PercuSense’s work in this area.

Post this

With the proper information and early warning, people with diabetes can intervene early to address the underlying cause and help prevent dangerous progression and hospitalization due to DKA. Many people with diabetes are not aware when their ketone levels might be increasing, and because DKA is infrequent, they often do not have easy access to a blood ketone meter. PercuSense's sensor system will be designed to alert users of increasing ketone levels and continue to monitor these levels after intervention. The system combines the benefits of continuous glucose monitoring while adding the safeguard of continuous ketone monitoring, which does not exist in any current commercial product.

"DKA is a constant, lurking risk for every person living with type 1 diabetes, regardless of whether they have been managing diabetes for ten days or ten years, and even more of a concern for those using or considering SGLT2 inhibitors. A system that can provide both continuous glucose and ketone monitoring (CGKM) can remove this danger, reducing the mental burden and improving the lives of people with type 1 diabetes. Our hope is that CGKM will be the standard of care in the future, and we are excited to support PercuSense's work in this area."
– Sean Sullivan, PhD, Type 1 Diabetes Program Officer, Helmsley Charitable Trust

The award builds off of the University of Melbourne and PercuSense's foundational work developing and testing a continuous ketone sensor system for human feasibility studies, which was funded by a grant from Helmsley to the University of Melbourne. The sensor will employ PercuSense's novel sensor platform technology that enables low cost, continuous measurement of multiple parameters inside the body.

PercuSense will develop the technology and complete first-in-human testing in collaboration with Dr. David O'Neal and the University of Melbourne.

"PercuSense is honored and excited to be selected by the Helmsley Charitable Trust to continue this important development program. We believe that expanding continuous monitoring beyond glucose for people with diabetes will help prevent DKA, increase peace of mind, and ultimately reduce the daily burden of managing diabetes."
– Brian Kannard, CEO, PercuSense

About PercuSense
PercuSense is focused on developing next generation continuous sensing platforms that enable prediction, intervention, and prevention in chronic diseases and acute conditions including diabetes management and in-hospital monitoring. PercuSense's unique technology enables low-cost monitoring of a variety of analytes, including glucose, lactate, oxygen, and ketones, to bring affordable and actionable continuous monitoring to the market. PercuSense's vision is to provide the right information in the right moment in order to improve outcomes, cost, and burden in settings and diseases across the healthcare spectrum. For more information, please visit percusense.com.

About The Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $2.5 billion for a wide range of charitable purposes. The Helmsley Type 1 Diabetes Program is one of the largest private foundation funders of T1D in the nation, focused on understanding the disease, developing better treatments, and improving care and access. For more information on Helmsley and its programs, visit http://www.helmsleytrust.org.

For inquiries, please contact Brian Kannard at [email protected] or (661) 425-7015.

SOURCE PercuSense, Inc.

Related Links

http://www.percusense.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.